Venetoclax Combo Approved for Older Patients With Acute Myeloid Leukemia

The FDA has now granted full approval to venetoclax (Venclexta®, AbbVie Inc. and Genentech Inc.) in combination with azacitidine, decitabine, or low-dose cytarabine (LDAC) for patients with previously untreated acute myeloid leukemia (AML) who are at least 75 years of age or who have comorbidities that prevent them from receiving intensive induction chemotherapy. Previously, this venetoclax combination therapy was granted accelerated approval in 2018 for use in this same patient population. The ...
Continue reading

Ibrutinib Plus Venetoclax in Relapsed/Refractory CLL: Peter Hillmen, MBChB, PhD

​For patients experiencing aggressive chronic lymphocytic leukemia (CLL), chemoimmunotherapy often leads to remission, but remission is frequently followed by disease relapse. A new treatment option may soon emerge for these patients: the CLARITY study, a phase 2 clinical trial, has found that the combination of ibrutinib plus venetoclax produces minimal residual disease (MRD)-negative responses in individuals with relapsed and/or refractory CLL, with promising rates of progression-free and over...
Continue reading

Ibrutinib/Venetoclax Promising in Relapsed/Refractory CLL

​CLARITY, a phase 2 clinical trial, reports that the combination of ibrutinib plus venetoclax in relapsed/refractory chronic lymphocytic leukemia (CLL) produces minimal residual disease (MRD)-negative responses, with promising rates of progression-free and overall survival. While some patients with CLL have indolent disease, for which treatment is not needed, others experience an aggressive progression of their cancer. For these patients, chemoimmunotherapy treatments such as fludarabine/cycloph...
Continue reading

Venetoclax for CLL/SLL With Matthew S. Davids, MD, MMSc

The FDA has recently expanded the label of venetoclax (Venclexta®, AbbVie Inc. and Genetech Inc.) to now include the treatment of adults with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), including those requiring initial therapy. Venetoclax is a targeted therapy that binds to the BCL-2 protein, which stimulates apoptosis—programmed cell death—in cancer cells. Matthew S. Davids, MD, MMSc, Assistant Professor at Harvard Medical School, and colleagues conducted earlier re...
Continue reading

FDA Approval: Venetoclax for CLL and SLL

The FDA has now approved venetoclax (Venclexta®, AbbVie Inc. and Genetech Inc.) for treatment of adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). "Patients never treated for their CLL have had to rely largely on chemotherapy as their initial treatment," said Michael Hallek, MD, lead investigator of the CLL14 study, Professor and Chairman at the Internal Medicine and Center of Integrated Oncology at the University Hospital Cologne in Germany. "The a...
Continue reading

Subscribe

Get the latest updates delivered to your inbox!

Follow Us

Copyright © 2021 Oncology Data Advisor. All rights reserved.